<DOC>
	<DOCNO>NCT02250937</DOCNO>
	<brief_summary>If read sign form behalf potential participant , please note : Any time word `` , '' `` , '' `` I , '' `` '' appear , meant apply potential participant . The goal clinical research study compare well two different schedule give busulfan fludarabine cladribine stem cell transplant patient AML MDS may help control disease . The safety drug combination also study .</brief_summary>
	<brief_title>Allogeneic Transplantation Using Timed Sequential Busulfan , Cladribine , Fludarabine Conditioning Patients With Acute Myelogenous Leukemia ( AML ) Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Central Venous Catheter : If choose take part study , chemotherapy , drug study , stem cell transplant give vein central venous catheter ( CVC ) . A CVC sterile flexible tube needle place large vein local anesthesia . Blood sample also draw CVC . The CVC remain body treatment . Your doctor explain procedure detail , require sign separate consent form . For stem cell transplant , day receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . Study Groups : You randomly assign ( flip coin ) 1 2 study group : - Group 1 receive busulfan Days -13 -12 , busulfan , fludarabine , cladribine Days -6 -3 . - Group 2 receive receive busulfan Days -20 -13 , busulfan , fludarabine , cladribine Days -6 -3 . You 50/50 chance assign either group . Both group stem cell transplant . Study Drug Administration : If Group 1 , receive busulfan vein 3 hour Day -13 Day -12 . You receive either outpatient clinic inpatient hospital . If Group 2 , receive dose busulfan vein 3 hour Day -20 Day -13 . You receive either outpatient clinic inpatient hospital . For arm , 11 sample blood ( 1-2 teaspoon time ) drawn pharmacokinetic ( PK ) test time point receive first dose busulfan . For Group 1 , Day -13 . For Group 2 , Days -20 -13 . The study staff tell blood test schedule . PK test measure amount study drug body different time point help doctor decide dose busulfan Days -6 -3 . If doctor think need , PK blood test may also do Day -6 dose busulfan . A heparin lock line place vein low number needle stick need draws . If possible PK test perform technical reason , take study receive standard fix dose busulfan . On Days -11 -8 , receive anything . On Day -7 , admit hospital receive fluid vein . On Days -6 -3 , receive busulfan vein 3 hour , fludarabine vein 1 hour , cladribine vein 2 hour day . On Day 0 , receive stem cell transplant vein . On Days 3 4 , stem cell relate match unrelated donor , receive cyclophosphamide 3 hour day vein help low risk GVHD . Starting Day +5 , receive Tacrolimus nonstop vein able take mouth help low risk graft-versus-host disease ( GVHD ) . You take Tacrolimus mouth 2 time day 3 month . After , Tacrolimus dose may lower GVHD . Your doctor discus . Starting 1 week transplant , receive filgrastim injection skin 1 time day blood cell level return normal . Filgrastim design help growth white blood cell . Study Testing : While hospital , check side effect part standard care . Blood ( 2 teaspoon ) draw every day check side effect , routine test , check blood count , check kidney liver function , check infection . As part standard care , remain hospital 3-4 week transplant . After send home hospital , must remain Houston area check infection transplant side effect 3 month transplant . During time , return clinic least 1 time week . At visit , blood ( 2 teaspoon ) draw routine test . About 1 , 3 , 6 , 12 month transplant : - You physical exam . - Blood ( 5 teaspoon ) draw see body react transplant . - If doctor think need , bone marrow aspiration check status disease . To collect bone marrow aspiration , area hip site numb anesthetic , small amount bone marrow withdrawn large needle . Length Study : You study 1 year transplant . You may take study early disease get bad , intolerable side effect , unable follow study direction . You talk study doctor want leave study early . If take study early , still may need return routine follow-up visit transplant , doctor think need . It may life-threatening leave study begin receive study drug receive stem cell . This investigational study . Busulfan , fludarabine , cladribine FDA approve commercially available . It investigational give cladribine combination busulfan fludarabine stem cell transplant . Up 116 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients biopsyproven acute myeloid leukemia myelodysplastic syndrome persistent disease remission . 2 . HLAidentical sibling 8/8 match unrelated donor transplant . 3 . Patients age 18 70 year old . Eligibility pediatric patient determine conjunction MDACC pediatrician . Patients age 217 year old may enrol least 10 adult ( age 1870 year old ) assess safety Day 30 , define Statistical Considerations section . 4 . Direct Bilirubin &lt; 1 mg/dl ALT &lt; 3 time upper limit normal . 5 . Creatinine clearance &gt; 50 ml/min ( calculated creatinine clearance permit ) . 6 . Adequate pulmonary function FEV1 , FVC DLCO &gt; /=50 % expect corrected hemoglobin and/or volume . Children unable perform pulmonary function test ( e.g. , less 7 year old ) pulse oximetry &gt; /= 92 % room air . 7 . LVEF &gt; /= 40 % . 8 . Patient , LAR , parent able sign inform consent . Able give assent patient age 717 . 9 . Negative Beta HCG test woman child bear potential , define postmenopausal 12 month previous surgical sterilization . Women child bear potential must willing use effective contraceptive measure study . 10 . Performance score &gt; /= 70 Karnofsky/Lansky PS 0 1 ( ECOG &lt; /=1 ) . 1 . Prior allogeneic autologous transplantation . 2 . Uncontrolled infection . 3 . HIV seropositivity . 4 . HCT Comorbidity Index score &gt; 3 . The principal investigator final arbiter eligibility comorbidity score &gt; 3 .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Cladribine</keyword>
	<keyword>Leustatin</keyword>
	<keyword>2-CdA</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Methotrexate</keyword>
</DOC>